A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
A research study of the drug amrubicin in patients with cancer of the thymus (thymoma or
thymic carcinoma). We hope to learn whether this drug is an effective and safe treatment for
thymic cancers.